(Q39903491)

English

Adoptive immunotherapy using human peripheral blood lymphocytes transferred with RNA encoding Her-2/neu-specific chimeric immune receptor in ovarian cancer xenograft model

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

15 September 2017

Adoptive immunotherapy using human peripheral blood lymphocytes transferred with RNA encoding Her-2/neu-specific chimeric immune receptor in ovarian cancer xenograft model (English)

1 reference

Europe PubMed Central

PubMed publication ID

15 September 2017

0 references

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

author name string

S H Yoon

1

1 reference

Europe PubMed Central

PubMed publication ID

15 September 2017

J M Lee

2

1 reference

Europe PubMed Central

PubMed publication ID

15 September 2017

H I Cho

3

1 reference

Europe PubMed Central

PubMed publication ID

15 September 2017

E K Kim

4

1 reference

Europe PubMed Central

PubMed publication ID

15 September 2017

H S Kim

5

1 reference

Europe PubMed Central

PubMed publication ID

15 September 2017

M Y Park

6

1 reference

Europe PubMed Central

PubMed publication ID

15 September 2017

T G Kim

7

1 reference

Europe PubMed Central

PubMed publication ID

15 September 2017

publication date

19 December 2008

1 reference

Europe PubMed Central

PubMed publication ID

15 September 2017

Cancer Gene Therapy

1 reference

Europe PubMed Central

PubMed publication ID

15 September 2017

16

1 reference

Europe PubMed Central

PubMed publication ID

15 September 2017

6

1 reference

Europe PubMed Central

PubMed publication ID

15 September 2017

489-497

1 reference

Europe PubMed Central

PubMed publication ID

15 September 2017

Selective growth, in vitro and in vivo, of individual T cell clones from tumor-infiltrating lymphocytes obtained from patients with melanoma

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2008.98

21 January 2018

Adoptive-cell-transfer therapy for the treatment of patients with cancer

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2008.98

21 January 2018

T cell-encoded CD80 and 4-1BBL induce auto- and transcostimulation, resulting in potent tumor rejection

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2008.98

21 January 2018

Primary human lymphocytes transduced with NY-ESO-1 antigen-specific TCR genes recognize and kill diverse human tumor cell lines

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2008.98

21 January 2018

Cancer regression in patients after transfer of genetically engineered lymphocytes

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2008.98

21 January 2018

Immunotherapy of cancer using systemically delivered gene-modified human T lymphocytes

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2008.98

21 January 2018

Generation and targeting of human tumor-specific Tc1 and Th1 cells transduced with a lentivirus containing a chimeric immunoglobulin T-cell receptor

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2008.98

21 January 2018

Adoptive transfer of gene-engineered CD4+ helper T cells induces potent primary and secondary tumor rejection

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2008.98

21 January 2018

Selective cytotoxic T-lymphocyte targeting of tumor immune escape variants

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2008.98

21 January 2018

Genetically engineered T cells expressing a HER2-specific chimeric receptor mediate antigen-specific tumor regression

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2008.98

21 January 2018

Targeting immune effector molecules to human tumor cells through genetic delivery of 5T4-specific scFv fusion proteins

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2008.98

21 January 2018

Gene therapy. Safer and virus-free?

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2008.98

21 January 2018

LMO2-associated clonal T cell proliferation in two patients after gene therapy for SCID-X1

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2008.98

21 January 2018

Mutagenesis and oncogenesis by chromosomal insertion of gene transfer vectors.

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2008.98

21 January 2018

Genotoxicity of retroviral integration in hematopoietic cells.

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2008.98

21 January 2018

High-efficiency transfection of primary human and mouse T lymphocytes using RNA electroporation

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2008.98

21 January 2018

Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2008.98

21 January 2018

HER2-positive circulating tumor cells indicate poor clinical outcome in stage I to III breast cancer patients

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2008.98

21 January 2018

Phosphorylation of tyrosine 1248-ERBB2 measured by chemiluminescence-linked immunoassay is an independent predictor of poor prognosis in primary breast cancer patients.

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2008.98

21 January 2018

HER-2-positive metastatic breast cancer: optimizing trastuzumab-based therapy

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2008.98

21 January 2018

Her-2/neu and EGFR tyrosine kinase activation predict the efficacy of trastuzumab-based therapy in patients with metastatic breast cancer

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2008.98

21 January 2018

Phase I dose escalation and pharmacokinetic study of lapatinib in combination with trastuzumab in patients with advanced ErbB2-positive breast cancer

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2008.98

21 January 2018

Receptor blockade with monoclonal antibodies as anti-cancer therapy

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2008.98

21 January 2018

ErbB2 potentiates breast tumor proliferation through modulation of p27(Kip1)-Cdk2 complex formation: receptor overexpression does not determine growth dependency

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2008.98

21 January 2018

Clinical trials of Herceptin(trastuzumab).

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2008.98

21 January 2018

Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2008.98

21 January 2018

CD4+ T cells are required for secondary expansion and memory in CD8+ T lymphocytes

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2008.98

21 January 2018

Tumor-specific CD4+ T cells have a major "post-licensing" role in CTL mediated anti-tumor immunity

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2008.98

21 January 2018

CD8 lethargy in the absence of CD4 help.

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2008.98

21 January 2018

Defective CD8 T Cell Memory Following Acute Infection Without CD4 T Cell Help

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2008.98

21 January 2018

Critical role of the Th1/Tc1 circuit for the generation of tumor-specific CTL during tumor eradication in vivo by Th1-cell therapy.

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2008.98

21 January 2018

Requirement for CD4 T Cell Help in Generating Functional CD8 T Cell Memory

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2008.98

21 January 2018

T cell retargeting with MHC class I-restricted antibodies: the CD28 costimulatory domain enhances antigen-specific cytotoxicity and cytokine production

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2008.98

21 January 2018

Natural killer cell cytotoxicity of breast cancer targets is enhanced by two distinct mechanisms of antibody-dependent cellular cytotoxicity against LFA-3 and HER2/neu.

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2008.98

21 January 2018

A listing of human tumor antigens recognized by T cells: March 2004 update

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2008.98

21 January 2018

Efficient genetic modification of murine dendritic cells by electroporation with mRNA

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2008.98

7 January 2021

based on heuristic

inferred from DOI database lookup

Coexpression of the type 1 growth factor receptor family members HER-1, HER-2, and HER-3 has a synergistic negative prognostic effect on breast carcinoma survival

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2008.98

7 January 2021

based on heuristic

inferred from DOI database lookup

Augmented HER-2 specific immunity during treatment with trastuzumab and chemotherapy

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2008.98

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1038/CGT.2008.98

1 reference

Europe PubMed Central

PubMed publication ID

15 September 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

15 September 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q39903491&oldid=2203248395"